Home › Clear-cell metastatic renal cell carcinoma › California › San Diego
Clear-cell metastatic renal cell carcinoma clinical trials in San Diego, CA
3 studies for Clear-cell metastatic renal cell carcinoma are looking for participants at sites in and around San Diego (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
- NEO-811 San Diego Site, San Diego
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
RecruitingPhase 3
- Research Site, San Diego
- Research Site, La Jolla · 11 mi away
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingPhase 1/2
- UC San Diego Medical Center - Bankers Hill, San Diego
- UC San Diego McGrath Outpatient Pavilion - Hillcrest, San Diego
- UC San Diego Medical Center - Hillcrest, San Diego
- and 5 more
Clear-cell metastatic renal cell carcinoma trials in other cities
- Baldwin Park, CA7 studies
- New York City, NY5 studies
- Dallas, TX5 studies
- Nashville, TN5 studies
- Rochester, MN4 studies
- Waukegan, IL4 studies
- Cleveland, OH4 studies
- St. Louis, MO4 studies
- Ann Arbor, MI3 studies
- San Francisco, CA3 studies
- Omaha, NE3 studies
- Houston, TX3 studies
Other studies in San Diego
- Non-Small Cell Lung Cancer48 studies
- Breast Cancer41 studies
- Cancer (all types)32 studies
- Prostate Cancer31 studies
- Metastatic Cancer30 studies
- Colorectal Cancer25 studies
- Ovarian Cancer24 studies
- Pancreatic Cancer24 studies
- Lung Cancer23 studies
- Obesity23 studies
- Heart Failure23 studies
- Depression21 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.